EN DE
Watch Aptamer Sciences Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Aptamer Sciences Inc (291650) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Aptamer Sciences Inc stock KRW 1,598, price KRW 2,180, that is 26.7% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

AS Aptamer Sciences Inc logo Thin data Nov 16, 2026

Aptamer Sciences Inc

291650 · KQ

Expensive (fair value 27% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Quality 42/100 
Expensive Growth (revenue 5y +72.6 %/yr in KRW) 
Mixed vs. peers (4/8) 
Fair value 1,598 KRW · Overvalued 
Negative free cash flow 
Narrow moat 12/100
Thin data 
Estimate
Watch Aptamer Sciences Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

21,413 KRW 950.00 KRW Fair Value 1,598 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 950.00 KRW – 21,413 KRW · fair‑value band 1,199 KRW – 1,998 KRW · the 2,180 KRW price screens above the 1,598 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Aptamer Sciences in your weekly email

Every Wednesday you see whether Aptamer Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms.

Show moreShow less

The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders.

It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. Aptamer Sciences Inc was founded in 2011 and is headquartered in Seongnam-si, South Korea.

Stock analysis

Aptamer Sciences Inc (291650) currently trades at 2,180 KRW, while our estimate is 1,598 KRW, 27% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,199 KRW (bear) to 1,998 KRW (bull), the price of 2,180 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Aptamer Sciences Inc reported revenue of 3.5B KRW in FY2025 versus 269M KRW in FY2021, a compound +89.9%/yr. Reported net income was −8.6B KRW in FY2025.

Key figures

Market cap 114B KRW (≈ $85.2M) Micro · P/S ratio 66.9 · Return on equity −42.5% · Return on assets (EBIT) −21.7% (5-year average) · Operating margin −129% · Revenue growth (YoY) +292% · Free cash flow −9.7B KRW · Net debt 7.0B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 44% below its 52-week high and 129% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −27%, 291650 screens richer than that median.

Fair Value

Bear 1,199 KRW Fair Value 1,598 KRW Bull 1,998 KRW
Price 2,180 KRW · Downside -26.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 95
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 45
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 38
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+223.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+113.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,716.8% (2020) → −222.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

291650 screens overvalued: fair value 27% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Aptamer Sciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside −26.7% · Below median
Profitability
Return on assets −21.0% · Above median
Operating margin (12 months) −128.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 291.5% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.04× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 291650
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 291650
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 291650
argenx SE ARGX $950.95 $908.40 −4% vs 291650
CSL Limited CSL A$199.55 A$186.49 −7% vs 291650
Moderna, Inc MRNA $215.27 $135.64 −37% vs 291650
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 291650
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 291650
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 291650
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 291650

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aptamer Sciences Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Aptamer Sciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/291650

Frequently asked questions

Is Aptamer Sciences Inc (291650) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 1,598 KRW versus a price of 2,180 KRW, about 27% lower (overvalued).
What is the fair value of 291650?
Our estimate for Aptamer Sciences Inc is 1,598 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 2,180 KRW.
What is the quality score of 291650?
Aptamer Sciences Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aptamer Sciences Inc (291650)?
Our calculated price target is the estimate of 1,598 KRW (as of Nov 16, 2026). Cautious scenario 1,199 KRW, optimistic scenario 1,998 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Aptamer Sciences Inc stock forecast for 2026?
Our estimate puts fair value at 1,598 KRW, about 27% lower versus a price of 2,180 KRW (overvalued). Cautious scenario 1,199 KRW, optimistic scenario 1,998 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Aptamer Sciences Inc (291650)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aptamer Sciences Inc it is 1,598 KRW per share (as of Nov 16, 2026), against a price of 2,180 KRW.
Is Aptamer Sciences Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 291650 trades above its calculated fair value: price 2,180 KRW, fair value 1,598 KRW, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 291650?
No. The price is what the market pays today (2,180 KRW); the fair value is what the company's own numbers justify (1,598 KRW). For Aptamer Sciences Inc the two are 581.90 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Aptamer Sciences Inc worth?
The market values Aptamer Sciences Inc at about 114B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 2,180 KRW; our models calculate a fair value of 1,598 KRW per share.
What do the bullish and bearish scenarios say about 291650?
Our models span a range for Aptamer Sciences Inc: cautious scenario 1,199 KRW, base 1,598 KRW, optimistic 1,998 KRW per share (as of Nov 16, 2026, price 2,180 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aptamer Sciences Inc (291650)?
Balance-sheet figures for Aptamer Sciences Inc (as of Nov 16, 2026): return on equity −42.5%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 291650 from its 52-week high?
Aptamer Sciences Inc trades at 2,180 KRW, about 44% below its 52-week high of 3,882 KRW and 129% above the low of 950.00 KRW (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 1,598 KRW is for.
Which stocks are comparable to Aptamer Sciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aptamer Sciences Inc stock attractive at the current price?
The data as of Nov 16, 2026: price 2,180 KRW, calculated fair value 1,598 KRW (−27%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Aptamer Sciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aptamer Sciences Inc (291650)?
The closing price on Nov 17, 2026 was 2,180 KRW. Our estimate is 1,598 KRW, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aptamer Sciences Inc right now?
The price sits above even our optimistic bull case (1,998 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Aptamer Sciences Inc

How large is the market capitalisation of Aptamer Sciences Inc (291650)?
The market capitalisation of Aptamer Sciences Inc is 114B KRW (≈ $85.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aptamer Sciences Inc (291650)?
The price-to-sales ratio of Aptamer Sciences Inc is 66.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Aptamer Sciences Inc (291650)?
The return on equity (ROE) of Aptamer Sciences Inc is −42.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aptamer Sciences Inc (291650)?
On an EBIT basis the return on assets of Aptamer Sciences Inc is −21.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aptamer Sciences Inc (291650)?
The operating margin of Aptamer Sciences Inc is −129% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aptamer Sciences Inc (291650)?
Revenue at Aptamer Sciences Inc is growing 292% versus a year earlier (3y avg +114%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Aptamer Sciences Inc (291650) generate?
The free cash flow of Aptamer Sciences Inc is −9.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Aptamer Sciences Inc (291650) carry?
The net debt of Aptamer Sciences Inc is 7.0B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Aptamer Sciences Inc in the live analysis

One click puts Aptamer Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.